Certain Options of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017. (2025)

Table of Contents

EOM Pharmaceuticals Holdings, Inc. IMUC US4525364026 Latest news about EOM Pharmaceuticals Holdings, Inc. Chart EOM Pharmaceuticals Holdings, Inc. Company Profile References

EOM PHARMACEUTICALS HOLDINGS, INC.

Add to a list

To use this feature you must be a member

Log inSign up

EOM Pharmaceuticals Holdings, Inc.

Equities

IMUC

US4525364026

Delayed OTC Markets Other stock markets 21:39:39 14/03/2025 +04			5-day change	1st Jan Change
0.1550 ^USD	0.00%		-2.52%	-8.18%

09-06	EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	CI
08-02	EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	CI

October 16, 2017

Certain Options of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017. These Options will be under lockup for 90 days starting from 18-JUL-2017 to 16-OCT-2017.Details:The officers, directors and certain of stockholders have agreed that they will not offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any shares of common stock or any securities convertible into or exchangeable for common stock, for a period of 90 days of the underwriting agreement without the prior written consent of Maxim Group LLC.

Latest news about EOM Pharmaceuticals Holdings, Inc.

EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	06/09/23	CI
EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	02/08/23	CI
EOM Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	20/12/22	CI
ImmunoCellular Therapeutics Ltd. has Changed its Name to EOM Pharmaceuticals Holdings, Inc	10/11/22	CI
EOM Pharmaceuticals Holdings, Inc. announced that it has received $0.75 million in funding	12/09/22	CI
EOM Pharmaceuticals Holdings, Inc. announced a financing transaction	26/08/22	CI
EOM Pharmaceuticals Holdings, Inc. has filed an IPO in the amount of $25 million.	24/06/22	CI
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	24/06/22	CI
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	10/02/22	CI
EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. in a reverse merger transaction.	02/12/21	CI
	18/10/18	CI
ImmunoCellular Therapeutics, Ltd. Announces Executive Changes, Effective October 15, 2018	16/10/18	CI
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	17/08/18	CI
ImmunoCellular Therapeutics Is Considering Strategic Alternatives	13/08/18	CI
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	15/05/18	CI
ImmunoCellular Therapeutics, Ltd. Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program	12/04/18	CI
ImmunoCellular Therapeutics, Ltd., Q4 2017 Earnings Call, Mar 13, 2018	14/03/18
ImmunoCellular Therapeutics, Ltd. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	14/03/18	CI
ImmunoCellular Considers Strategic Alternatives	22/02/18	CI
ImmunoCellular Therapeutics, Ltd. Achieves Stem-to-T-Cell Research Immuno-Oncology Program	14/12/17	CI
ImmunoCellular Therapeutics, Ltd., Q3 2017 Earnings Call, Nov 21, 2017	22/11/17
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	22/11/17	CI
Certain Common Stock of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017.	16/10/17	CI
Certain Options of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017.	16/10/17	CI
Certain Restricted Stock Units of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017.	16/10/17	CI

Chart EOM Pharmaceuticals Holdings, Inc.

Duration

Period

IMUC: Dynamic Chart

Company Profile

EOM Pharmaceutical Holdings, Inc., through its wholly owned subsidiary EOM Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its pipeline includes its lead compound EOM613, an investigational novel dynamically dual-acting immunomodulator. EOM613 is a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects. Human cell culture studies demonstrate that EOM613 can suppress or stimulate monocytes and macrophages depending on the activation state and environment of those key immune cells, resulting in either further activation or suppression. Its pipeline also includes EOM147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases.

Employees

Sector

More about the company

Stock Market
Equities
IMUC Stock
News EOM Pharmaceuticals Holdings, Inc.
Certain Options of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017.

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools! d : : BENEFIT NOW

"); for (var element in ICConf) { if (document.getElementById("zpp"+element)) { document.getElementById("zpp"+element).innerHTML = ""; } } InvestingChannelQueue.push(function() { ic_page = InvestingChannel.UAT.Run("5c5a75c3-8896-4592-98f8-dc06e6fdcc56"); }); } $(document).ready(function() {gaEvent('adspv', 'InvestingChannel_v2', 'US');});googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_AE');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '120790047');googletag.enableServices();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });

Certain Options of ImmunoCellular Therapeutics, Ltd. are subject to a Lock-Up Agreement Ending on 16-OCT-2017. (2025)

References

https://ae.marketscreener.com/quote/stock/EOM-PHARMACEUTICALS-HOLDI-120790047/news/Certain-Options-of-ImmunoCellular-Therapeutics-Ltd-are-subject-to-a-Lock-Up-Agreement-Ending-on-16-34939237/